Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

被引：2

作者：

Martinez, Carmen ^{[1
]}

Rodriguez-Calvillo, Mercedes ^{[2
]}

Terol, Maria Jose ^{[3
]}

Xicoy, Blanca ^{[4
]}

Garcia-Sanz, Ramon ^{[5
]}

Perez-Ceballos, Elena ^{[6
]}

Cantalapiedra, Alberto ^{[7
]}

Domingo-Domenech, Eva ^{[8
]}

Hernandez, Miguel ^{[9
]}

Sampol, Antonia ^{[10
]}

Espeso, Manuel ^{[11
]}

Briones, Javier ^{[12
]}

Lopez, Javier ^{[13
]}

Sureda, Anna ^{[14
]}

机构：

[1] Hosp Clin Barcelona, Barcelona, Spain

[2] Complejo Hosp Navarra, Navarra, Spain

[3] Hosp Clin Univ Valencia, Valencia, Spain

[4] Univ Autonoma Barcelona, IJC ICO Badalona, Hosp Germans Trias & Pujol, Badalona, Spain

[5] Univ Hosp Salamanca, Dept Haematol, Salamanca, Spain

[6] Hosp Morales Meseguer, Murcia, Spain

[7] Hosp Rio Hortega, Valladolid, Spain

[8] Inst Catala Oncol, Lhospitalet De Llobregat, Spain

[9] Hosp Univ Canarias, Tenerife, Spain

[10] Hosp Univ Son Dureta, Palma De Mallorca, Spain

[11] Hosp Reg Univ Carlos Haya, Malaga, Spain

[12] Autonomous Univ Barcelona, Barcelona, Spain

[13] Hosp Univ Ramon y Cajal, Serv Hematol & Hemoterapia, Madrid, Spain

[14] Addenbrookes Hosp, Dept Haematol, Cambridge CB2 2QQ, England

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.1630.1630

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1630

引用

页数：2

共 47 条

[1] Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy
Martinez, Carmen
Diaz-Lopez, Antonio
Rodriguez-Calvillo, Mercedes
Garcia-Sanz, Ramon
Jose Terol, Maria
Perez-Ceballos, Elena
Jimenez, Maria J.
Cantalapiedra, Alberto
Domingo-Domenech, Eva
Jose Rodriguez, Maria
Sampol, Antonia
Espeso, Manuel
Lopez, Francisco-Javier
Briones, Javier
Garcia, Juan F.
Sureda, Anna
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (06) : 859 - 867
[2] Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
Garcia-Sanz, Ramon
Sureda, Anna
Alonso-Alvarez, Sara
Pilar Gonzalez, Ana
Rodriguez, Antonia
Salar, Antonio
de la Cruz, Fatima
Domingo, Eva
Moreno, Miriam
Lopez, Javier, Sr.
Luis Pinana, Jose
Rodriguez, Gabriela
Canales, Miguel
Manuel Gurierrez, Antonio
Lopez-Guillermo, Armando
Dolores Caballero, Maria
Jimenez, Silvia
Martinez, Carmen
BLOOD, 2015, 126 (23)
[3] A phase II trial of Rituximab plus ESHAP as salvage chemotherapy in relapsed/refractory aggressive histology non-Hodgkin's lymphoma.
Piliotis, EG
Mangel, J
Buckstein, R
Imrie, K
Spaner, D
Reis, M
Foden, C
Boudreau, A
Richardson, P
Richardson, J
Berinstein, N
BLOOD, 2003, 102 (11) : 288B - 288B
[4] Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
Garcia-Sanz, Ramon
Sureda, Anna
Gonzalez, Ana Pilar
De la Cruz, Fatima
Sanchez-Gonzalez, Blanca
Rodriguez, Antonia
Domingo-Domenech, Eva
Miriam, Moreno
Miriam, Moreno
Lopez, Javier, Sr.
Jose, Pinana Luis
Rodriguez, Gabriela
Canales, Miguel
Gutierrez, Antonio
Caballero, Maria Dolores
Martinez, Carmen
BLOOD, 2016, 128 (22)
[5] EVALUATION OF THE BRENUTXIMAB VEDOTIN REGIME AND ESHAP (BRESHAP) IN LYMPHOMA PRIMARY RESISTANT HODGKIN'S OR IN FIRST RELAPSE: RESULTS PRELIMINARY A TRIAL PHASE I-II OF THE SPANISH GROUP OF LYMPHOMAS AND TRANSPLANTATION OF BONE MARROW (GELTAMO)
Garcia Sanz, R.
Sureda, A.
Gonzalez, A. P.
Salar, A.
Rodriguez, A.
De La Cruz, F.
Domiingo-Domenech, E.
Canales, M.
Lopez, J.
Moreno, M.
Rodriguez, G.
Jose Luis, P.
Rodriguez, M. J.
Lopez-Guillermo, A.
Caballero, M. D.
Jimenez, S.
Martinez, C.
HAEMATOLOGICA, 2015, 100 : 9 - 9
[6] Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial
Sureda, Anna
Pilar Gonzalez, Ana
Nunez, Javier
Briones, Javier
De la Cruz, Fatima
Domenech Eva, Domingo
Maria Hernandez, Francisca
Jose Terol, Maria
Amutio, Elena
Cordoba, Raul
Martinez, Carmen
Moreno, Miriam
Rodriguez Izquierdo, Antonia
Del Campo, Raquel
Greil, Richard
Romero, Samuel
Garcia-Sanz, Ramon
BLOOD, 2021, 138
[7] Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis
Broeckelmann, Paul J.
Mueller, Horst
Gillessen, Sarah
Yang, Xiaoqin
Koeppel, Larissa
Pilz, Veronika
Marinello, Patricia
Kaskel, Peter
Raut, Monika
Fuchs, Michael
Borchmann, Peter
Engert, Andreas
von Tresckow, Bastian
LEUKEMIA, 2022, 36 (03) : 772 - 780
[8] Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis
Paul J. Bröckelmann
Horst Müller
Sarah Gillessen
Xiaoqin Yang
Larissa Koeppel
Veronika Pilz
Patricia Marinello
Peter Kaskel
Monika Raut
Michael Fuchs
Peter Borchmann
Andreas Engert
Bastian von Tresckow
Leukemia, 2022, 36 : 772 - 780
[9] Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)
Bastos-Oreiro, Mariana
Lopez, Nieves
Gomez, Pilar
Marta, Liebana
LLorente, Laura
Gutierrez, Antonio
Domingo Domenech, E. V. A.
Vidal Macenido, Maria Jesus
Del Campo, Raquel
Bento, Leyre
Garcia, Daniel
Santero, Miriam
Perez De Oteyza, Jaime
Navarro, Belen
Rodriguez Izquierdo, Antonia
Garcia-Sanz, Ramon
BLOOD, 2019, 134
[10] High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy
Rauf, Muhammad Shahzad
Maghfoor, Irfan
Elhassan, Tusneem Ahmed M.
Akhtar, Saad
MEDICAL ONCOLOGY, 2015, 32 (01)

← 1 2 3 4 5 →